We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Although adaptive seamless design (ASD) in clinical trials offers many benefits, “there is no free lunch,” said Sue-Jane Wang, associate director at the FDA’s Office of Biostatistics.